{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:53:55Z","timestamp":1774342435819,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jemermed.2017.08.024","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T02:16:18Z","timestamp":1507688178000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider"],"prefix":"10.1016","volume":"54","author":[{"given":"Maryann","family":"Mazer-Amirshahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Pourmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2017.08.024_bib1","unstructured":"Centers for Disease Control and Prevention, 2014 National Diabetes Statistics Report. Available at: https:\/\/www.cdc.gov\/diabetes\/data\/statistics\/2014statisticsreport.html. Accessed March 3,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib2","unstructured":"American Diabetes Association, Statistics about diabetes. Available at: http:\/\/www.diabetes.org\/diabetes-basics\/statistics\/. Accessed March 17,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib3","series-title":"Emergency Department Visits for Adults with Diabetes","author":"Washington","year":"2010"},{"key":"10.1016\/j.jemermed.2017.08.024_bib4","unstructured":"National Diabetes Education Initiative, Diabetes management guidelines. Available at: http:\/\/www.ndei.org\/ADA-diabetes-management-guidelines-pharmacologic-therapy-for-type-2-diabetes.aspx.html. Accessed March 17,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0895-4356(97)00024-3","article-title":"Rates of hypoglycemia in users of sulfonylureas","volume":"50","author":"van Staa","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jemermed.2017.08.024_bib6","unstructured":"Novo Nordisk, Trebisa prescribing information. Available at: http:\/\/www.novo-pi.com\/tresiba.pdf. Accessed March 18,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2015.04.002","article-title":"Clinical use of insulin degludec","volume":"109","author":"Vora","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jemermed.2017.08.024_bib8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes: a phase 3, randomized, open-label, treat-to-target noninferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2017.08.024_bib9","unstructured":"Eli Lilly and Company, Basaglar prescribing information. Available at: http:\/\/uspl.lilly.com\/basaglar\/basaglar.html#pi. Accessed March 22,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/193229681200600229","article-title":"Clinical use of U-500 regular insulin: review and meta-analysis","volume":"6","author":"Reutrakul","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jemermed.2017.08.024_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/diaspect.29.3.136","article-title":"An overview of concentrated insulin products","volume":"29","author":"Painter","year":"2016","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jemermed.2017.08.024_bib12","doi-asserted-by":"crossref","first-page":"e000074","DOI":"10.1136\/bmjdrc-2014-000074","article-title":"Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world U.S. cohort study","volume":"3","author":"Eby","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4158\/EP13407.OR","article-title":"Healthcare costs and adherence with human regular U-500 versus high dose U-100 insulin in patients with diabetes","volume":"20","author":"Eby","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jemermed.2017.08.024_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1358\/dot.2014.50.12.2233894","article-title":"Technosphere inhaled insulin (Afrezza)","volume":"50","author":"Rendell","year":"2014","journal-title":"Drugs Today"},{"key":"10.1016\/j.jemermed.2017.08.024_bib15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S2213-8587(15)00280-6","article-title":"Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis","volume":"3","author":"Pittas","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 2","key":"10.1016\/j.jemermed.2017.08.024_bib16","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide-1 receptor agonists. A review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-5996-5-47","article-title":"Direct cardiovascular effects of glucagon-like peptide-1","volume":"5","author":"Sheikh","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jemermed.2017.08.024_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jemermed.2017.08.024_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Sing","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jemermed.2017.08.024_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and a reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2017.08.024_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.diabres.2016.08.011","article-title":"Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: a systematic review","volume":"121","author":"Bihan","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jemermed.2017.08.024_bib22","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"10.1016\/j.jemermed.2017.08.024_bib23","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: viewpoints on the way to consensus","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib24","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study","volume":"31","author":"DeFronzo","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib25","unstructured":"Merck and Co. Inc. Januvia prescribing information. Available at:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021995s019lbl.pdf. Accessed March 31,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/dc15-0347","article-title":"Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains","volume":"38","author":"Azoulay","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib27","first-page":"2450","article-title":"Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure","volume":"8","author":"Kankanala","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jemermed.2017.08.024_bib28","unstructured":"U.S. Food and Drug Administration, DPP-4 inhibitors for type 2 diabetes: drug safety communication\u2014may cause severe joint\u00a0pain.\u00a0Available at: https:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm460238.htm. Accessed March 31,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s13181-014-0383-6","article-title":"Clinical effects of exposure to DPP-4 inhibitors as reported to the National Poison Data System","volume":"10","author":"Russell","year":"2014","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.jemermed.2017.08.024_bib30","unstructured":"AstraZeneca Pharmaceuticals, Symlin prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021332s007_S016.pdf. Accessed April 1,\u00a02017."},{"issue":"suppl 3","key":"10.1016\/j.jemermed.2017.08.024_bib31","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jemermed.2017.08.024_bib32","unstructured":"Janssen Pharmaceuticals. Invokana prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204042s011lbl.pdf. Accessed April 2,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib33","article-title":"The role of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes","author":"Steen","year":"2017","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jemermed.2017.08.024_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","article-title":"Renal gluconeogenesis: its importance in human glucose homeostasis","volume":"24","author":"Gerich","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jemermed.2017.08.024_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 5","key":"10.1016\/j.jemermed.2017.08.024_bib36","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.jcjd.2015.09.001","article-title":"The role of the kidney and SGLT2 inhibitors in type 2 diabetes","volume":"39","author":"Katz","year":"2015","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jemermed.2017.08.024_bib37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jemermed.2017.08.024_bib38","first-page":"26","article-title":"Drugs for diabetes: part 8 SGLT-2 inhibitors","volume":"19","author":"MacEwan","year":"2012","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jemermed.2017.08.024_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jemermed.2017.08.024_bib40","unstructured":"U.S. Food and Drug Administration, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm. Accessed April 2,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib41","unstructured":"U.S. Food and Drug Administration, FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm461449.htm. Accessed April 2,\u00a02017."},{"key":"10.1016\/j.jemermed.2017.08.024_bib42","unstructured":"U.S. Food and Drug Administration, Canagliflozin (Invokana, Invokamet): Drug Safety Communication\u2014Clinical trial results find increased risk of leg and foot amputation. Available at: https:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm501565.htm. Accessed April 2,\u00a02017."}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467917307308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467917307308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:46Z","timestamp":1760027986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467917307308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0736467917307308"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2017.08.024","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2017.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}